drugset
drugset / Trial / NCT04203433

A Study of DLX105-DMP in Subjects With Plaque Psoriasis

NCT04203433 ↗

Phase 1 Completed 10 enrolled DelArrivo, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Pilot, Open-Label Study in Subjects with Mild-to-Moderate Plaque Psoriasis to Investigate the Safety, Tolerability, and Preliminary Efficacy of a Four-Week Multidose Regimen of DLX105-DMP Administered to a Target Lesion

Timeline

Start
2022-03-21
Primary completion
2022-09-01
Completion
2022-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DLX105-DMP Unknown 1 mg Topical

Indications

psoriasis